

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/027417-2022>

Contract

## **(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.**

Newcastle University  
Durham University  
Northumbria University Newcastle Newcastle  
University of Sunderland  
Teesside University  
University of Bath on behalf of the SETsquared

F03: Contract award notice

Notice identifier: 2022/S 000-027417

Procurement identifier (OCID): ocids-h6vhtk-03719a

Published 30 September 2022, 9:41am

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

Newcastle University

Newcastle University, Procurement Services, Kingsgate

Newcastle

NE1 7RU

#### **Contact**

Mrs Natalie Morton

#### **Email**

[natalie.morton@ncl.ac.uk](mailto:natalie.morton@ncl.ac.uk)

**Telephone**

+44 1912086396

**Country**

United Kingdom

**Region code**

UKC - North East (England)

**Internet address(es)**

Main address

<https://www.ncl.ac.uk>

Buyer's address

<https://www.ncl.ac.uk>

**I.1) Name and addresses**

Durham University

The Palatine Centre, Stockton Road

**Email**

[Edwin.e.milligan@durham.ac.uk](mailto:Edwin.e.milligan@durham.ac.uk)

**Country**

United Kingdom

**Region code**

UKC - North East (England)

**Internet address(es)**

Main address

<https://www.durham.ac.uk>

### **I.1) Name and addresses**

Northumbria University Newcastle Newcastle

Newcastle upon Tyne

#### **Email**

[Hugh.Rhodes@northumbria.ac.uk](mailto:Hugh.Rhodes@northumbria.ac.uk)

#### **Country**

United Kingdom

#### **Region code**

UKC - North East (England)

#### **Internet address(es)**

Main address

<https://northumbria.ac.uk>

### **I.1) Name and addresses**

University of Sunderland

Sunderland

#### **Email**

[Cheryl.Holmstrom@sunderland.ac.uk](mailto:Cheryl.Holmstrom@sunderland.ac.uk)

#### **Country**

United Kingdom

#### **Region code**

UKC - North East (England)

**Internet address(es)**

Main address

<https://Sunderland.ac.uk>

**I.1) Name and addresses**

Teesside University

Middlesbrough, Tees Valley

**Email**

[David.Pratt@tees.ac.uk](mailto:David.Pratt@tees.ac.uk)

**Country**

United Kingdom

**Region code**

UKC - North East (England)

**Internet address(es)**

Main address

<https://www.tees.ac.uk/>

**I.1) Name and addresses**

University of Bath on behalf of the SETsquared

Claverton Down, Bath

**Email**

[pb487@bath.ac.uk](mailto:pb487@bath.ac.uk)

**Country**

United Kingdom

**Region code**

UK - United Kingdom

**Internet address(es)**

Main address

<https://www.bath.ac.uk/>

**I.2) Information about joint procurement**

The contract involves joint procurement

The contract is awarded by a central purchasing body

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Education

---

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title**

(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.

Reference number

DN621813

**II.1.2) Main CPV code**

- 79400000 - Business and management consultancy and related services

**II.1.3) Type of contract**

Services

#### **II.1.4) Short description**

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US\$92Bn in 2019 and is expected to reach US\$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US\$35.5Bn Million in 2018 and is projected to reach US\$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.

The initial brief of the executive will be to:

Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;

Phase (2) September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board

Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;

b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO.

c. Provide to the University of Bath all matters necessary for Research England reporting requirements.

Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding

Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

#### **II.1.6) Information about lots**

This contract is divided into lots: No

**II.1.7) Total value of the procurement (excluding VAT)**

Value excluding VAT: £30,000

**II.2) Description****II.2.3) Place of performance**

NUTS codes

- UKC - North East (England)

**II.2.4) Description of the procurement**

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US\$92Bn in 2019 and is expected to reach US\$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US\$35.5Bn Million in 2018 and is projected to reach US\$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.

The initial brief of the executive will be to:

Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;

Phase (2) September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board

Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;

b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO.

c. Provide to the University of Bath all matters necessary for Research England reporting requirements.

Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure

seed finance, draft and submit Innovate UK proposal for preclinical funding

Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

#### **II.2.5) Award criteria**

Quality criterion - Name: Ability to meet the required job description / Weighting: Pass/Fail

Quality criterion - Name: Quality: Ability to meet the Job Description / Weighting: Pass/Fail and 60%

Quality criterion - Name: Equity / Weighting: Pass/Fail

Price - Weighting: 40

#### **II.2.11) Information about options**

Options: No

#### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: Yes

Identification of the project

Northern Accelerator programme involving funding from both the European Regional Development Funding (ERDF) and Research England



---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Restricted procedure

#### **IV.1.3) Information about a framework agreement or a dynamic purchasing system**

The procurement involves the setting up of a dynamic purchasing system

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: No

### **IV.2) Administrative information**

#### **IV.2.1) Previous publication concerning this procedure**

Notice number: [2022/S 186-528050](#)

---

## **Section V. Award of contract**

### **Contract No**

(NU/1433-37)

A contract/lot is awarded: Yes

### **V.2) Award of contract**

#### **V.2.1) Date of conclusion of the contract**

21 September 2022

#### **V.2.2) Information about tenders**

Number of tenders received: 3

Number of tenders received from SMEs: 3

Number of tenders received from tenderers from other EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 3

Number of tenders received by electronic means: 3

The contract has been awarded to a group of economic operators: No

**V.2.3) Name and address of the contractor**

Cambridge Drug Discovery

35 Tunwells Lane, Great Shelford,

Cambridgeshire

CB22 5LJ

Country

United Kingdom

NUTS code

- UKC - North East (England)

The contractor is an SME

Yes

**V.2.4) Information on value of contract/lot (excluding VAT)**

Total value of the contract/lot: £30,000

---

## **Section VI. Complementary information**

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

Newcastle University

Tyne and Wear

NE1 7RU

Country

United Kingdom

#### **VI.4.2) Body responsible for mediation procedures**

Newcastle University

Tyne and Wear

Country

United Kingdom

#### **VI.4.3) Review procedure**

Precise information on deadline(s) for review procedures

The University will incorporate a standstill period at the point information on the award of the

contract is communicated to tenderers. That notification will provide full information on the award decision. The standstill period, which will be for a minimum of 10 calendar days, provides time for unsuccessful tenderers to challenge the award decision before the contract is entered into.

The Public Contracts Regulations 2015 (SI 2015 No 102) provide for aggrieved parties who

have been harmed or are at risk of harm by a breach of the rules to take action in the High

Court (England, Wales and Northern Ireland) within 30 days of knowledge or constructive knowledge of breach.

**VI.4.4) Service from which information about the review procedure may be obtained**

Newcastle University

Tyne and Wear

Country

United Kingdom